Vertex Pharmaceuticals is hoping to build upon its existing rare blood disease treatment portfolio, teaming up with Orna Therapeutics’ ReNAgade in efforts to develop next-gen gene therapies for ...

Vertex Pharmaceuticals will work together with Orna Therapeutics over the next three years to develop technology that would help enable “in vivo” gene therapies for sickle cell disease and ...

Orna Therapeutics, through its wholly owned subsidiary ReNAgade Therapeutics, announced a three-year strategic research collaboration with Vertex Pharmaceuticals (VRTX) to utilize Orna’s novel ...

Orna Therapeutics, through its wholly owned subsidiary ReNAgade Therapeutics Inc., announced its new three-year research collaboration with Vertex on Tuesday. Orna acquired Cambridge-based ...

(RTTNews) - Orna Therapeutics, through its subsidiary ReNAgade Therapeutics, announced a three-year strategic research collaboration with Vertex Pharmaceuticals (VRTX) to utilize Orna's ...

At close: January 27 at 3:00:00 PM EST ...

Vertex Pharmaceuticals will work together with Orna Therapeutics over the next three years to develop technology that would help enable “in vivo” gene therapies for sickle cell disease and beta ...

At close: January 23 at 3:00:00 PM EST ...

As of January 13 at 3:00:00 PM EST. Market Open.

Orna Therapeutics has entered into a three-year strategic research collaboration with Vertex Pharmaceuticals, which will see the latter leverage Orna's lipid nanoparticle (LNP) delivery technology.

Padma Shri for Arundhati Bhattacharya: PSBs Role in Nation-Building Arundhati Bhattacharya, former SBI chairperson, receives Padma Shri, acknowledging the crucial role of public sector banks in ...